Company intelligence / Profile preview
Sedor Pharmaceuticals, LLC
Paoli, Pennsylvania, United Statessedorpharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sedor Pharmaceuticals received FDA approval for SESQUIENT (fosphenytoin sodium for injection) in November 2020 for the treatment of status epilepticus in adult and pediatric patients. SESQUIENT is the only FDA-approved room-temperature stable formulation of fosphenytoin sodium, allowing point-of-care storage and efficient administration in emergency settings.[5][9]
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ligand PharmaceuticalsLos Altos Pharmaceuticals
Beyond the preview
Go deeper on Sedor Pharmaceuticals, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sedor Pharmaceuticals, LLC.